** Cancer diagnostics firm NeoGenomics' NEO.O shares down 4.4% before the bell on Tues to $10.60 as it looks to raise capital

** NEO late Mon unveiled private offering of $275 mln convertible bonds (CBs) due 2032

** Co intends to use some net offering proceeds, along with cash, to repurchase a portion of its 0.25% CBs due 2028

** Also plans to use proceeds to pay cost of capped call transactions and repurchase up to $25 mln of shares to facilitate hedging by investors in the new CBs

** Through Mon, NEO stock had rallied 49% QTD, leaving it down ~6% YTD

** Fort Myers, Florida-based firm has about $1.4 bln market cap

** Avg rating of 12 analysts is "buy"; median PT $14, per LSEG data